Skip to main content
Logo Logo Logo
  • Investors
    • Investors
    • Stock Information
    • Investors Toolkit
    • Events & Presentations
    • Financial Information
    • SEC Filings
    • Corporate Governance
    • Analyst Coverage
    • Fundamentals
    • Ownership Profile
    • Annual Meetings
    • Press Releases
    • Capella (Scientific Presentations)
    • FAQs
  • Medical Professionals
    • For Medical Professionals
    • Genetic Testing & Counseling
    • Early Access Program
    • Medical Publication Support
    • Investigator Initiated Studies (IIS)
  • Patients
    • For Patients
    • Amyloidosis
    • Acute Hepatic Porphyria
    • Primary Hyperoxaluria
    • Patient Services
    • Genetic Testing and Counseling
    • Patient Advocacy
  • Careers
    • About Careers
    • Working at Alnylam
    • Search Jobs
    • Diversity, Equity & Inclusion
  • Quick Links
    • Clinical Trials
    • Corporate Responsibility
    • Diversity, Equity & Inclusion
    • Press Releases
    • Capella (Scientific Presentations)
    • Medical Resources (RNAi Science)
    • Contact Us
  • Follow Us
    • Youtube
    • Facebook
    • X
    • LinkedIn
    • Instagram
    • Sign Up
  • Global English
    • Austria Deutsch
    • Belgium Nederlands Français
    • Brazil Português
    • Canada Français English
    • Denmark Dansk
    • France Français
    • Germany Deutsch
    • Ireland English
    • Italy Italiano
    • Japan 日本語
    • Luxembourg Français Deutsch
    • Netherlands Nederlands
    • Portugal Português
    • Spain Español
    • Sweden Svenska
    • Switzerland Français Deutsch Italiano
    • Taiwan 繁體中文
    • United Kingdom English
  • Our Company
    • About Alnylam
    • Leadership
    • Diversity, Equity & Inclusion
    • Patient Access Philosophy
    • Corporate Responsibility
    • Alnylam Challengers
    • Transparency
    • Grants & Giving
    • Investigator Initiated Studies (IIS)
  • Our Science
    • The Science of RNAi
    • Delivery Platforms
    • Making Our Medicines
    • Therapeutic Areas
    • Pipeline
    • Clinical Trials
    • Scientific Advisory Board
    • Intellectual Property
    • Capella (Scientific Presentations)
  • Our Products
    • Product Listing
  • Our News
    • Newsroom
    • Press Releases
    • Capella (Scientific Presentations)
    • Media Kit
  • Global English
    • Austria Deutsch
    • Belgium Nederlands Français
    • Brazil Português
    • Canada Français English
    • Denmark Dansk
    • France Français
    • Germany Deutsch
    • Ireland English
    • Italy Italiano
    • Japan 日本語
    • Luxembourg Français Deutsch
    • Netherlands Nederlands
    • Portugal Português
    • Spain Español
    • Sweden Svenska
    • Switzerland Français Deutsch Italiano
    • Taiwan 繁體中文
    • United Kingdom English
  • Our Company
    • About Alnylam
    • Leadership
    • Diversity, Equity & Inclusion
    • Patient Access Philosophy
    • Corporate Responsibility
    • Alnylam Challengers
    • Transparency
    • Grants & Giving
    • Investigator Initiated Studies (IIS)
  • Our Science
    • The Science of RNAi
    • Delivery Platforms
    • Making Our Medicines
    • Therapeutic Areas
    • Pipeline
    • Clinical Trials
    • Scientific Advisory Board
    • Intellectual Property
    • Capella (Scientific Presentations)
  • Our Products
    • Product Listing
  • Our News
    • Newsroom
    • Press Releases
    • Capella (Scientific Presentations)
    • Media Kit
  • Investors

    Investors
    • Investors
    • Stock Information
    • Investors Toolkit
    • Events & Presentations
    • Financial Information
    • SEC Filings
    • Corporate Governance
    • Analyst Coverage
    • Fundamentals
    • Ownership Profile
    • Annual Meetings
    • Press Releases
    • Capella (Scientific Presentations)
    • FAQs
  • Medical Professionals

    Medical Professionals
    • For Medical Professionals
    • Genetic Testing & Counseling
    • Early Access Program
    • Medical Publication Support
    • Investigator Initiated Studies (IIS)
  • Patients

    Patients
    • For Patients
    • Amyloidosis
    • Acute Hepatic Porphyria
    • Primary Hyperoxaluria
    • Patient Services
    • Genetic Testing and Counseling
    • Patient Advocacy
  • Careers

    Careers
    • About Careers
    • Working at Alnylam
    • Search Jobs
    • Diversity, Equity & Inclusion
  • Quick Links

    Quick Links
    • Clinical Trials
    • Corporate Responsibility
    • Diversity, Equity & Inclusion
    • Press Releases
    • Capella (Scientific Presentations)
    • Medical Resources (RNAi Science)
    • Contact Us
  • Follow Us

    Follow Us
    • Youtube
    • Facebook
    • X
    • LinkedIn
    • Instagram
    • Sign Up

Our News

Share this:

Culture of Innovation Brings Recognition as a Best Workplace for Innovators by Fast Company

August 4, 2021

Seth Levine

Sr. Director, Global Head of Corporate Brand & Creative, Alnylam Pharmaceuticals

"Innovation" is a term that’s used quite liberally in biotech, technology and a lot of other industries, but when you're creating something totally new, from scratch, as Alnylam has done with RNAi therapeutics, nearly everything that you do truly is an innovation. In our journey, some innovations were BIG and some were smaller, but through sustained research and development efforts over the past 20 years, our people have pioneered the science and processes that provided the critical breakthroughs that make RNAi therapeutics possible. And as a result, our medicines are now helping people who just a few years ago had little reason for hope.

At Alnylam, we like to describe our journey as having been "founded on optimistic discovery and built through perseverant innovation." We use these words because our founders believed that the Nobel Prize-winning discovery of RNAi (RNA interference) in worms held great potential for humans and could be translated into a revolutionary new class of medicines to treat diseases that had been deemed "undruggable." The prospect meant that we could potentially bring new therapies to tens of thousands of people who currently had no or limited treatment options. Then, through successes and setbacks, we did just that, culminating with the approval of the world's first approved RNAi therapeutic in 2018 and subsequent approvals of the only other approved RNAi therapeutics in 2019 and 2020.

It's because of where we started from in 2002, and what we needed accomplish to get to where we are today as the leading RNAi therapeutics company, that innovation has always been at the core of our culture. In fact, "Innovation and Discovery" is one of our Core Values as a company and we believe that it is because of the expectation that we will do new, amazing and impactful things as individuals and collectively, that we have been as successful as we have been.

While our employees and peers in the biopharma industry have long known this to be true, it's especially gratifying to be recognized for our innovative culture and the impact of our innovation more broadly which is why we're thrilled to have been named a Best Workplace for Innovators for 2021 by Fast Company, and be ranked #11 out of 100. Fast Company has recognized Alnylam for innovation before - as one of its 50 Most Innovative Companies for 2019. 

Free-flowing cross-functional collaboration, including our practice of "20% time," is a key component of innovation at Alnylam. 

We nurture our culture of innovation in a multitude of different ways, from our approach to R&D to employee development programs to our diversity, equity and inclusion (DE&I) efforts which aim to “harness the power of AND” to tap great thinking and transformative ideas from all parts and corners of our organization. Another way that we nurture this kind of thinking is through our practice of allowing employees to set aside up to 20% of their time to explore their professional passions and take on new challenges – even those that may be outside of their given role. And it was as a result of this 20% time that a small, cross-functional team, of their own volition, set out to solve how to deliver siRNAs (small interfering RNAs, which we synthesize) to the central nervous system (CNS) – something that had never been done before. This work created a new research track for the company expanding our research focus to include the CNS and ocular tissues. It also led directly to a nearly $1 billion research collaboration with Regeneron which we hope will yield transformative medicines for patients living with CNS and ocular diseases.

Check out the full 2021 Best Workplaces for Innovators list here and we invite you to learn more about how innovators can make an impact for science, patients and in their respective professional fields with a career at Alnylam. If you’re an innovator, seeking the company of other innovators at a company recognized for its innovation, perhaps this is your moment to join us!

Tags

Careers & Culture, Articles, Fast Company, Awards, Our Culture

Related Content See All News ›
Careers & Culture 11 Years, 11 Insights: What The Boston Globe Top Place to Work Survey Reveals About Our ...
Careers & Culture Five in A Row! Alnylam Named a 2025 Best Workplace for Innovators by Fast Company
Careers & Culture Challenge Accepted: How Culture Powers Innovation at Alnylam

Share this:

Categories

  • Leadership
  • Perspectives
  • RNAi
  • Patient Focus
  • Responsibility
  • Careers & Culture

Content Types

  • Articles
  • Podcasts
  • Presentations
  • Videos
See All News ›
Related Content See All News ›
Careers & Culture 11 Years, 11 Insights: What The Boston Globe Top Place to Work Survey Reveals About Our ...
Careers & Culture Five in A Row! Alnylam Named a 2025 Best Workplace for Innovators by Fast Company
Careers & Culture Challenge Accepted: How Culture Powers Innovation at Alnylam
See All News ›

FOLLOW US

Visit our social channels to learn more about the innovative work we are doing at Alnylam.

  • Our Company
  • Our Science
  • Our Products
  • Our News
  • Investors
  • Medical Professionals
  • Patients
  • Job Seekers
  • Clinical Trials
  • Corporate Responsibility
  • Diversity, Equity & Inclusion
  • Press Releases
  • Capella
  • Medical Resources (RNAi Science)
  • Contact Us
  • Sign Up For Updates
  • Privacy Policy
  • Media Kit
  • Legal Notice
  • Site Map
  • Sign Up For Updates

Copyright ©  Alnylam Pharmaceuticals, Inc. — All Rights Reserved

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals.

Links to all outside sites are provided as a reference for our visitors.

Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site